The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Pricey Arthritis Drug Effective in Small Fraction of Ulcerative Colitis Cases

Pricey Arthritis Drug Effective in Small Fraction of Ulcerative Colitis Cases

May 9, 2017 • By Gene Emery

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—Pfizer’s expensive arthritis drug tofacitinib has been shown to produce a remission in nearly 1 in 5 patients with moderate to severe ulcerative colitis, but long-term remission persists in fewer than half of those cases.

You Might Also Like
  • Adalimumab, Tacrolimus Effective for Treating Refractory Ulcerative Colitis
  • Golimumab Effective as Maintenance Treatment for Active Ulcerative Colitis
  • Methotrexate for Ulcerative Colitis Yields Mixed Results

In a series of studies published in the May 4 New England Journal of Medicine, researchers reported remission rates of 18.5% and 16.6% at 8 weeks. Rates with placebo were 8.2% (P=0.007) and 3.6% (P<0.001) respectively. Combined, 1,139 patients were treated.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the long-term test, which only included 593 volunteers who responded to induction therapy, the remission rate at the 52-week mark was 34.4% with 5 mg tofacitinib twice daily, which would cost nearly $50,000 per year according to Drugs.com.

At double the dose and an annual cost approaching $100,000, the success rate rose 6 additional percentage points, to 40.6%.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The long-term remission rate in the responders switched to placebo was 11.1% (P<0.001).

When the research team looked at mucosal healing, a dose response was also seen, with a rate of 37.4% with 5 mg of tofacitinib and 45.7% at the 10 mg dose. The rate was only 13.1% with placebo.

Pfizer paid for the study.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

While fewer than 1 in 13 of all volunteers showed a long-term response, the patient pool consisted of people for whom conventional therapy, such as glucocorticoids, azathioprine or infliximab, had failed or caused too many side effects.

In the induction studies, known as OCTAVE Induction 1 and OCTAVE Induction 2, more patients receiving the test drug developed an infection. The highest rate was 23.3% versus 18.2% for placebo.

Among patients who responded to the drug in the initial phase, infections were more common in the long-term test, known as OCTAVE Sustain. The rates were 39.8% with the high-dose therapy, 35.9% with lower-dose treatment and 24.2% with placebo. Most infections were ranked mild or moderate.

In the Sustain trial, the rates of herpes zoster infection were 0.5% with placebo, 1.5% with the 5 mg dose and 5.1% with the 10 mg dose.

“As compared with placebo, tofacitinib treatment was associated with increased levels of high-density lipoprotein and low-density lipoprotein cholesterol, more overall infections, and more cases of herpes zoster infection, so the benefit of this therapy comes at a price,” Dr. Sonia Friedman of the Brigham and Women’s Hospital Center for Crohn’s and Colitis says in an editorial. “Whether tofacitinib will be an essential therapy for ulcerative colitis remains to be determined in future trials.”2


References
  1. Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017 May 4;376(18):1723–1736. doi: 10.1056/NEJMoa1606910.
  2. Friedman S. Tofacitinib for ulcerative colitis—a promising step forward. N Engl J Med. 2017 May 4;376(18):1792–1793. doi: 10.1056/NEJMe1701505.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Tofacitinib, ulcerative colitis

You Might Also Like:
  • Adalimumab, Tacrolimus Effective for Treating Refractory Ulcerative Colitis
  • Golimumab Effective as Maintenance Treatment for Active Ulcerative Colitis
  • Methotrexate for Ulcerative Colitis Yields Mixed Results
  • Mucosal Healing Seen with Infliximab Biosimilar CT-P13 in Ulcerative Colitis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)